John Mariadason

BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

S Arulananda, M O’Brien, M Evangelista, TJ Harris, NS Steinohrt, LJ Jenkins, M Walkiewicz, RJJ O’Donoghue, AR Poh, B Thapa, DS Williams, T Leong, JM Mariadason, X Li, J Cebon, EF Lee, T John, W Douglas Fairlie

Journal article  |  2020  |  Cell Death Discovery

Abstract Despite having one of the lowest survival rates of all cancers, there have been no new approved treatments for malignant ..

Molecular regulators of lipid metabolism in the intestine - Underestimated therapeutic targets for obesity?

Mercedes Davalos-Salas, John M Mariadason, Matthew J Watt, Magdalene K Montgomery

Journal article  |  2020  |  Biochemical Pharmacology

The incidence of obesity and type 2 diabetes continues to rise across the globe necessitating the need to identify new therapeutic..

Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone

Katie L Owen, Linden J Gearing, Damien J Zanker, Natasha K Brockwell, Weng Hua Khoo, Daniel L Roden, Marek Cmero, Stefano Mangiola, Matthew K Hong, Alex J Spurling, Michelle McDonald, Chia-Ling Chan, Anupama Pasam, Ruth J Lyons, Hendrika M Duivenvoorden, Andrew Ryan, Lisa M Butler, John M Mariadason, Tri Giang Phan, Vanessa M Hayes, et al.

Journal article  |  2020  |  EMBO Reports

The latency associated with bone metastasis emergence in castrate-resistant prostate cancer is attributed to dormancy, a state in ..

Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer

David S Williams, Dmitri Mouradov, Clare Browne, Michelle Palmieri, Meg J Elliott, Rebecca Nightingale, Catherine G Fang, Rita Li, John M Mariadason, Ian Faragher, Ian T Jones, Leonid Churilov, Niall C Tebbutt, Peter Gibbs, Oliver M Sieber

Journal article  |  2020  |  Modern Pathology

TP53 mutations drive colorectal cancer development, with missense mutations frequently leading to accumulation of abnormal TP53 pr..

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets

David K Lau, Dmitri Mouradov, Wiphawan Wasenang, Ian Y Luk, Cameron M Scott, David S Williams, Yvonne H Yeung, Temduang Limpaiboon, George F Iatropoulos, Laura J Jenkins, Camilla M Reehorst, Fiona Chionh, Mehrdad Nikfarjam, Daniel Croagh, Amardeep S Dhillon, Andrew J Weickhardt, Toshihide Muramatsu, Yoshimasa Saito, Niall C Tebbutt, Oliver M Sieber, et al.

Journal article  |  2019  |  iScience

Biliary tract cancers (BTCs) currently have no approved targeted therapies. Although genomic profiling of primary BTCs has identif..

Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity

Mercedes Davalos-Salas, Magdalene K Montgomery, Camilla M Reehorst, Rebecca Nightingale, Irvin Ng, Holly Anderton, Sheren Al-Obaidi, Analia Lesmana, Cameron M Scott, Paul Ioannidis, Hina Kalra, Shivakumar Keerthikumar, Lars Togel, Angela Rigopoulos, Sylvia J Gong, David S Williams, Prusoth Yoganantharaja, Kim Bell-Anderson, Suresh Mathivanan, Yann Gibert, et al.

Journal article  |  2019  |  Nature Communications

Histone deacetylase 3 (Hdac3) regulates the expression of lipid metabolism genes in multiple tissues, however its role in regulati..

BRAF inhibitors synergize with BH3 mimetics to induce apoptosis in BRAF mutant colorectal cancer cells

Laura J Jenkins, Fiona Chionh, Ian Y Luk, Erinna F Lee, Amardeep S Dhillon, Niall Tebbutt, Walter D Fairlie, John M Mariadason

Conference Proceedings  |  2019  |  Molecular and Cellular Biology / Genetics

Identification of novel colorectal tumor suppressor genes through genome-wide promoter hypermethylation analysis

Sarah Bazzocco, Jose Higinio Dopeso, Agueda Martinez-Barriocanal, Estefania Anguita, Rocio Nieto, Alex Sanchez, John M Mariadason, Diego Arango

Conference Proceedings  |  2019  |  Molecular and Cellular Biology / Genetics

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

Erinna F Lee, Tiffany J Harris, Sharon Tran, Marco Evangelista, Surein Arulananda, Thomas John, Celeste Ramnac, Chloe Hobbs, Haoran Zhu, Gency Gunasingh, David Segal, Andreas Behren, Jonathan Cebon, Alexander Dobrovic, John M Mariadason, Andreas Strasser, Leona Rohrbeck, Nikolas K Haass, Marco J Herold, W Douglas Fairlie

Journal article  |  2019  |  Cell Death and Disease

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin

D Rao, AB Mallick, T Augustine, C Daroqui, J Jiffry, A Merla, I Chaudhary, R Seetharam, A Sood, S Gajavelli, S Aparo, L Rajdev, A Kaubisch, J Chuy, A Negassa, JM Mariadason, R Maitra, S Goel

Journal article  |  2019  |  Oncotarget